737-P: Physical Activity Levels among Latino Adults with Type 2 Diabetes

Autor: Charis B. Hoppe, Arianna J. Larez, Mary M. Conneely, David Kerr, Wendy C. Bevier, Jessikah Morales, Namino M. Glantz, Kong Y. Chen
Rok vydání: 2019
Předmět:
Zdroj: Diabetes. 68
ISSN: 1939-327X
0012-1797
DOI: 10.2337/db19-737-p
Popis: Physical activity (PA) is a cornerstone of type 2 diabetes (T2D) treatment. In the U.S, Latinos bear a disproportionate cardio-metabolic disease burden from T2D. The aim of this study was to determine levels and patterns of PA among free-living Latino adults with T2D comparing a ubiquitous consumer device with an established accelerometry method. Participants (57 women and 31 men, BMI (kg/m2) 32.2±7.9 and 29.9±4.5, waist circumference (WC cm) 97.1±30.1 and 93.7±33.0, and HbA1C% 8.0±2.0 and 8.1±1.8, respectively) wore a research device (Actigraph, wGT3X-BT, AG) on the dominant hip and a consumer device (Fitbit Charge 2™, FB) on the non-dominant wrist to monitor daily activity for one week [outcome measures estimated by steps and energy expenditure (EE)]. AG median steps/weekday (M-F) was 6990 (range 1091-25884) compared to 9329 (288-31669) using the FB data (p≤0.01). Both devices recorded higher number of steps on weekdays compared to weekends [AG 5608 (1066-19892) and FB 7577 (1023-23603), both p≤0.05]. This corresponded to activity-related energy-expenditure of 442 (63-1821) kcals/weekday and 361 (58-1396) kcals/weekend using AG and 2344 (1135-5802) kcals/weekday and 2178 (1378-4930) kcals/weekend by FB (including resting metabolic rate). AG and FB data were highly correlated to each other for daily steps (r’s>0.7, p’s In conclusion, to incentivize PA in Latino adults with T2D, considerations need to be made of the timing of measurements (weekdays versus weekends), gender and technologies used. Disclosure W.C. Bevier: Research Support; Self; Eli Lilly and Company. N.M. Glantz: Research Support; Self; Eli Lilly and Company. C.B. Hoppe: Research Support; Self; Eli Lilly and Company. J. Morales: Research Support; Self; Eli Lilly and Company. A.J. Larez: Research Support; Self; Eli Lilly and Company. M.M. Conneely: Research Support; Self; Eli Lilly and Company. K.Y. Chen: None. D. Kerr: Advisory Panel; Self; Ascensia Diabetes Care, Novo Nordisk A/S, Sanofi. Research Support; Self; Lilly Diabetes. Stock/Shareholder; Self; Glooko, Inc. Funding Eli Lilly and Company
Databáze: OpenAIRE
Externí odkaz: